aTyr Pharma ($LIFE) Failed Phase 3 Trial, Overstated Drug Potential, and 83% Stock Drop Case
$LIFE investors filed a claim against aTyr Pharma for overstating the effectiveness of its lead drug efzofitimod, misrepresenting the design and expectations of its Phase 3 trial, and misleading investors about its likelihood of FDA approval.
After announcing that the Phase 3 trial failed to meet its primary endpoint, $LIFE fell 83.1% from September 12, 2025, to September 15.
$LIFE investors can join this case to be notified about potential recovery.
Between January 16, 2024, and September 12, 2025, aTyr Pharma repeatedly told investors that its lead candidate, efzofitimod, was a promising treatment for pulmonary sarcoidosis. Executives described the drug as potentially “paradigm-shifting,” emphasized its clean safety profile, and claimed strong patient demand and engagement.
The company’s Phase 3 trial (EFZO-FIT) was designed to test efzofitimod’s ability to reduce steroid use—a primary treatment goal for sarcoidosis patients. aTyr management, including CEO Sanjay Shukla, said the trial was well-designed and powered to succeed, projecting topline data for Q3 2025 and expressing confidence in a clear regulatory path.
However, aTyr allegedly failed to disclose key risks in its trial design and efficacy assumptions. According to the complaint, the company underestimated placebo performance and overstated efzofitimod’s impact on steroid reduction. Internal modeling flaws and biological uncertainty made a statistically significant result far less likely than investors were led to believe.
On September 13, 2025, aTyr announced that efzofitimod failed to meet the primary endpoint in its Phase 3 trial. The drug did not significantly reduce steroid use compared to placebo, casting doubt on its approval prospects. Analysts responded swiftly—RBC Capital downgraded the stock and cut its price target from $16 to $1.50.
$LIFE dropped 83.1%, from $6.03 on September 12 to $1.02 by market close on September 15.
It misled investors about efzofitimod’s effectiveness and regulatory outlook.
It concealed weaknesses in its Phase 3 trial design and placebo assumptions.
It overstated the likelihood of clinical and commercial success.
Investors argue aTyr misled the market about the viability of its lead drug, resulting in severe losses when the trial failed and the truth was revealed.